{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:07:54Z","timestamp":1789243674697,"version":"build-2803163510"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Sichuan Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2026NSFSC1655"],"award-info":[{"award-number":["2026NSFSC1655"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116797","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:39:19Z","timestamp":1778071159000},"page":"116797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Deciphering spatial-temporal mechanisms of PD-1 blockade resistance via biologically informed machine learning"],"prefix":"10.1016","volume":"182","author":[{"given":"Liuguijie","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0005","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0010","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13811","article-title":"Quantitative systems pharmacology modeling of macrophage-targeted therapy combined with PD-L1 inhibition in advanced NSCLC","volume":"17","author":"Wang","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1>\/=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115119","article-title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: a pooled analysis in 935 patients","volume":"214","author":"Robert","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"6702","key":"10.1016\/j.intimp.2026.116797_bb0025","doi-asserted-by":"crossref","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116797_bb0035","doi-asserted-by":"crossref","first-page":"1363144","DOI":"10.3389\/fimmu.2024.1363144","article-title":"A review of mechanistic learning in mathematical oncology","volume":"15","author":"Metzcar","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2020.10.014","article-title":"Biologically informed neural networks predict drug responses","volume":"38","author":"Greene","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0050","article-title":"Spatial transcriptomics: integrating platforms and computational approaches for clinical insights","volume":"87","author":"Song","year":"2025","journal-title":"Biotechnol. Adv."},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10555-025-10304-z","article-title":"Spatial omics: applications and utility in profiling the tumor microenvironment","volume":"44","author":"See","year":"2025","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0060","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ccell.2024.09.001","article-title":"Spatial oncology: translating contextual biology to the clinic","volume":"42","author":"Gong","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0065","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and Immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung Cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116797_bb0070","doi-asserted-by":"crossref","first-page":"1368749","DOI":"10.3389\/fimmu.2024.1368749","article-title":"Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy","volume":"15","author":"Qin","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0075","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","article-title":"The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition","volume":"8","author":"Williams","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"7880","key":"10.1016\/j.intimp.2026.116797_bb0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","article-title":"Biologically informed deep neural network for prostate cancer discovery","volume":"598","author":"Elmarakeby","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0085","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cpt.3371","article-title":"Predicting survival in patients with advanced NSCLC treated with Atezolizumab using pre- and on-treatment prognostic biomarkers","volume":"116","author":"Benzekry","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116797_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0100","article-title":"Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures","volume":"6","author":"Peyraud","year":"2025","journal-title":"Cell Rep Med"},{"issue":"16","key":"10.1016\/j.intimp.2026.116797_bb0105","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0115","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol. Med."},{"issue":"18","key":"10.1016\/j.intimp.2026.116797_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186680","article-title":"Immune checkpoint inhibitors beyond progression in various solid tumors: a systematic review and pooled analysis","volume":"14","author":"Petrelli","year":"2025","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116797_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of Hyperprogressive disease during Cancer treatment with immune checkpoint inhibitors: a systematic review and Meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc-fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies","volume":"12","author":"Zhang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0140","doi-asserted-by":"crossref","unstructured":"S.F. Ngiow, S. Manne, Y.J. Huang, T. Azar, Z. Chen, D. Mathew, Q. Chen, O. Khan, J.E. Wu, V. Alcalde, A.J. Flowers, S. McClain, A.E. Baxter, M. Kurachi, J. Shi, A.C. Huang, J.R. Giles, A.H. Sharpe, D.A.A. Vignali, E.J. Wherry, LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity, Cell 187(16) (2024) 4336\u20134354 e19.","DOI":"10.1016\/j.cell.2024.07.018"},{"issue":"45","key":"10.1016\/j.intimp.2026.116797_bb0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2410911121","article-title":"Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade","volume":"121","author":"Arulraj","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0155","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116797_bb0160","doi-asserted-by":"crossref","unstructured":"J.C. Beltra, M.S. Abdel-Hakeem, S. Manne, Z. Zhang, H. Huang, M. Kurachi, L. Su, L. Picton, S.F. Ngiow, Y. Muroyama, V. Casella, Y.J. Huang, J.R. Giles, D. Mathew, J. Belman, M. Klapholz, H. Decaluwe, A.C. Huang, S.L. Berger, K.C. Garcia, E.J. Wherry, Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure, Immunity 56(12) (2023) 2699\u20132718 e11.","DOI":"10.1016\/j.immuni.2023.11.005"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0165","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","article-title":"Evolution of delayed resistance to immunotherapy in a melanoma responder","volume":"27","author":"Liu","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116797_bb0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/psp4.12594","article-title":"Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy","volume":"10","author":"Gonzalez-Garcia","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116797_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193262","article-title":"Optimizing anti-PD1 immunotherapy: An overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0180","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2026.116797_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125755","article-title":"Antibody-dependent cellular cytotoxicity of anti-programmed death-ligand 1 antibodies for T cells attenuate their antitumor efficacy in a murine tumor model","volume":"679","author":"Tamemoto","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molmed.2024.10.008","article-title":"Fc-optimized checkpoint antibodies for cancer immunotherapy","volume":"31","author":"Dahan","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","article-title":"Acidosis-mediated increase in IFN-gamma-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors","volume":"22","author":"Knopf","year":"2023","journal-title":"Mol. Cancer"},{"issue":"7670","key":"10.1016\/j.intimp.2026.116797_bb0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"issue":"6282","key":"10.1016\/j.intimp.2026.116797_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.116797_bb0210","doi-asserted-by":"crossref","unstructured":"W.Z. Snyder M, Lara B, Fimbres J, Pichardo T, Mazzilli S, Khan MM, Duggineni VK, Monti S, Sherr DH., The aryl hydrocarbon receptor controls IFN\u2014induced immune checkpoints PD-L1 and IDO via the JAK\/STAT pathway in lung adenocarcinoma, J. Immunol. (2025).","DOI":"10.1101\/2024.08.12.607602"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0215","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","article-title":"Metabolic communication in the tumour-immune microenvironment","volume":"24","author":"Kao","year":"2022","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40005-025-00791-1","article-title":"Quantitative systems pharmacology models: unleashing their potential in cancer immunotherapy","volume":"56","author":"Xue","year":"2025","journal-title":"J. Pharm. Investig."},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0225","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.trecan.2023.07.006","article-title":"Beyond matrix stiffness: targeting force-induced cancer drug resistance","volume":"9","author":"Kalli","year":"2023","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.it.2024.07.009","article-title":"The extracellular matrix in solid tumor immunotherapy","volume":"45","author":"Cho","year":"2024","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10928-024-09928-5","article-title":"Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC","volume":"51","author":"Ippolito","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.1211","article-title":"Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle","volume":"106","author":"Bartelink","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tips.2023.11.003","article-title":"Spatial pharmacology using mass spectrometry imaging","volume":"45","author":"Rajbhandari","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"16","key":"10.1016\/j.intimp.2026.116797_bb0250","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/0008-5472.CAN-24-0943","article-title":"Integration of clinical trial spatial multiomics analysis and virtual clinical trials enables immunotherapy response prediction and biomarker discovery","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116797_bb0255","doi-asserted-by":"crossref","first-page":"1700039","DOI":"10.3389\/fimmu.2025.1700039","article-title":"Epigenetic regulation of CD8(+) T cell exhaustion: recent advances and update","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0260","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1158\/0008-5472.CAN-22-3864","article-title":"Terminally exhausted CD8+ T cells resistant to PD-1 blockade promote generation and maintenance of aggressive cancer stem cells","volume":"83","author":"Hakravarti","year":"2023","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0265","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418985122","article-title":"Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1","volume":"122","author":"Mok","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0270","article-title":"4-1BB(+) Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy","volume":"6","author":"Cha","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005845","article-title":"Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets","volume":"11","author":"Laletin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","article-title":"Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response","volume":"134","author":"Haragan","year":"2019","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0290","article-title":"Predictive value of combined positive score and tumor proportion score for immunotherapy response in advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.intimp.2026.116797_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102418","article-title":"Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment","author":"Lindsay","year":"2025","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0300","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0305","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70403","article-title":"Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0315","first-page":"1121","article-title":"Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers","volume":"5","author":"Muquith","year":"2024","journal-title":"Nat. Can."},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0325","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0330","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0335","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1878-0261.13483","article-title":"Neoantigens in cancer immunotherapy: quantity vs. quality","volume":"17","author":"Wolf","year":"2023","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1013163","article-title":"Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions","volume":"21","author":"Voutouri","year":"2025","journal-title":"PLoS Comput. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0345","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41540-024-00415-8","article-title":"Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy","volume":"10","author":"Butner","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"26","key":"10.1016\/j.intimp.2026.116797_bb0355","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0360","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41588-024-01883-8","article-title":"MHC hammer reveals genetic and non-genetic HLA disruption in cancer evolution","volume":"56","author":"Puttick","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2026.116797_bb0365","doi-asserted-by":"crossref","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-gamma signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113014","article-title":"CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity","volume":"42","author":"House","year":"2023","journal-title":"Cell Rep."},{"issue":"35","key":"10.1016\/j.intimp.2026.116797_bb0375","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304190120","article-title":"The spread of interferon-gamma in melanomas is highly spatially confined, driving nongenetic variability in tumor cells","volume":"120","author":"Centofanti","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0380","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0385","first-page":"924","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.intimp.2026.116797_bb0390","doi-asserted-by":"crossref","first-page":"1602452","DOI":"10.3389\/fonc.2025.1602452","article-title":"Role of TGFbeta-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy","volume":"15","author":"Hou","year":"2025","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2026.116797_bb0395","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-beta signaling in health and disease","volume":"186","author":"Massague","year":"2023","journal-title":"Cell"},{"issue":"7693","key":"10.1016\/j.intimp.2026.116797_bb0400","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116797_bb0405","doi-asserted-by":"crossref","first-page":"1698088","DOI":"10.3389\/fimmu.2025.1698088","article-title":"TGF-beta-driven T-cell exclusion in ovarian cancer: single-cell and spatial transcriptomic views of immune low-response states","volume":"16","author":"He","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008721","article-title":"POSTN(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0415","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0420","doi-asserted-by":"crossref","first-page":"1348852","DOI":"10.3389\/fimmu.2024.1348852","article-title":"Opportunities and challenges for anti-CD47 antibodies in hematological malignancies","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188771","article-title":"CD47: beyond an immune checkpoint in cancer treatment","volume":"1877","author":"Bian","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"20","key":"10.1016\/j.intimp.2026.116797_bb0430","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0435","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0440","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0445","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0450","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s43556-025-00345-9","article-title":"CD39 and CD73: biological functions, diseases and therapy","volume":"6","author":"Shen","year":"2025","journal-title":"Mol Biomed"},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0455","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.intimp.2026.116797_bb0460","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","article-title":"Interleukin-1alpha release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity","volume":"42","author":"Hanggi","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0465","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0470","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/psp4.13258","article-title":"Uncovering the interleukin-12 pharmacokinetic desensitization mechanism and its consequences with mathematical modeling","volume":"14","author":"DeBonis","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116797_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110648","article-title":"Dual anti-PD-(L)1\/TGF-beta inhibitors in cancer immunotherapy - updated","volume":"122","author":"Karami","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0480","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0485","article-title":"Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy","volume":"5","author":"Shorer","year":"2025","journal-title":"Cell Genom"},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0490","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","article-title":"Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade","volume":"41","author":"Pai","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0495","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41590-022-01337-5","article-title":"Divergent clonal differentiation trajectories of T cell exhaustion","volume":"23","author":"Daniel","year":"2022","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116797_bb0500","article-title":"Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer","volume":"6","author":"Metoikidou","year":"2025","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0505","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41422-023-00831-1","article-title":"An invasive zone in human liver cancer identified by stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression","volume":"33","author":"Wu","year":"2023","journal-title":"Cell Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0510","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.trecan.2023.06.002","article-title":"Collagen architecture and signaling orchestrate cancer development","volume":"9","author":"Su","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0515","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s42003-025-09087-4","article-title":"Fibroblast TGF-beta signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance","volume":"8","author":"Lee","year":"2025","journal-title":"Commun Biol"},{"issue":"5","key":"10.1016\/j.intimp.2026.116797_bb0520","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","article-title":"Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics","volume":"43","author":"Liu","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.116797_bb0525","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","article-title":"Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures","volume":"43","author":"Tang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0530","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.10.023","article-title":"Tertiary lymphoid structures and cancer immunotherapy: from bench to bedside","volume":"6","author":"Peyraud","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0540","doi-asserted-by":"crossref","first-page":"2466308","DOI":"10.1080\/2162402X.2025.2466308","article-title":"Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma","volume":"14","author":"Ruiz-Torres","year":"2025","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0545","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41416-024-02882-6","article-title":"Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues","volume":"131","author":"Semba","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116797_bb0550","doi-asserted-by":"crossref","first-page":"1617906","DOI":"10.3389\/fimmu.2025.1617906","article-title":"Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0555","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-024-05035-8","article-title":"Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging","volume":"22","author":"Monkman","year":"2024","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0560","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.intimp.2026.116797_bb0565","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgae539","article-title":"Spatial organization and stochastic fluctuations of immune cells impact clinical responsiveness to immunotherapy in melanoma patients","volume":"3","author":"Giuliani","year":"2024","journal-title":"PNAS Nexus"},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0570","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","article-title":"The spatial organization of cDC1 with CD8+ T cells is critical for the response to immune checkpoint inhibitors in patients with melanoma","volume":"13","author":"Gobbini","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0575","article-title":"Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer","volume":"5","author":"Campbell","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0580","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00281-022-00974-0","article-title":"Highly multiplexed spatial profiling with CODEX: bioinformatic analysis and application in human disease","volume":"45","author":"Kuswanto","year":"2023","journal-title":"Semin. Immunopathol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116797_bb0585","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","article-title":"CODEX multiplexed tissue imaging with DNA-conjugated antibodies","volume":"16","author":"Black","year":"2021","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010183","article-title":"Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma","volume":"13","author":"Song","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0595","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/2767-9764.CRC-24-0201","article-title":"Spatial multiomics reveals Intratumoral immune heterogeneity with distinct cytokine networks in lung Cancer brain metastases","volume":"4","author":"Christensson","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-024-01188-4","article-title":"From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling","volume":"7","author":"Wang","year":"2024","journal-title":"npj Digital Medicine"},{"issue":"3","key":"10.1016\/j.intimp.2026.116797_bb0605","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/psp4.13288","article-title":"Accelerating virtual patient generation with a Bayesian optimization and machine learning surrogate model","volume":"14","author":"Iwata","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116797_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fsysb.2023.1099413","article-title":"MEMMAL: a tool for expanding large-scale mechanistic models with machine learned associations and big datasets","volume":"3","author":"Erdem","year":"2023","journal-title":"Front Syst Biol"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0615","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/jamia\/ocaf144","article-title":"Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling","volume":"33","author":"Melike Sirlanci","year":"2026","journal-title":"J. Am. Med. Inform. Assoc."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0620","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0625","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41467-024-50426-6","article-title":"CGMega: explainable graph neural network framework with attention mechanisms for cancer gene module dissection","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012908","article-title":"Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome","volume":"21","author":"Santurio","year":"2025","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.intimp.2026.116797_bb0635","doi-asserted-by":"crossref","first-page":"1463915","DOI":"10.3389\/fimmu.2024.1463915","article-title":"Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies","volume":"15","author":"Lefevre","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116797_bb0640","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.tips.2023.09.009","article-title":"Development of bispecific T cell engagers: harnessing quantitative systems pharmacology","volume":"44","author":"Qi","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0645","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-024-51329-2","article-title":"Deciphering cell-cell communication at single-cell resolution for spatial transcriptomics with subgraph-based graph attention network","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0650","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae666","article-title":"stHGC: a self-supervised graph representation learning for spatial domain recognition with hybrid graph and spatial regularization","volume":"26","author":"Wang","year":"2024","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.intimp.2026.116797_bb0655","article-title":"Quantitative calibration of a spatial QSP model identifies fibroblast impact on HCC immunotherapy","author":"Zhang","year":"2025","journal-title":"bioRxiv [Preprint]"},{"issue":"10","key":"10.1016\/j.intimp.2026.116797_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102750","article-title":"Quantifying Intratumoral heterogeneity and Immunoarchitecture generated in-silico by a spatial quantitative systems pharmacology model","volume":"15","author":"Nikfar","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0665","article-title":"Cytometry masked autoencoder: An accurate and interpretable automated immunophenotyper","volume":"5","author":"Kim","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0670","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","article-title":"PKCalpha\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma","volume":"77","author":"Wei","year":"2022","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0675","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005414","article-title":"Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model","volume":"10","author":"Sove","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"6547","key":"10.1016\/j.intimp.2026.116797_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba2609","article-title":"Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade","volume":"372","author":"Berry","year":"2021","journal-title":"Science"},{"issue":"7980","key":"10.1016\/j.intimp.2026.116797_bb0685","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"7994","key":"10.1016\/j.intimp.2026.116797_bb0690","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0695","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10637-025-01523-w","article-title":"Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application","volume":"43","author":"Yao","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.intimp.2026.116797_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1732193","article-title":"Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome","volume":"16","author":"Perkins","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116797_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107742","article-title":"Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer","volume":"171","author":"Doerfler","year":"2025","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0710","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12964-024-01884-4","article-title":"Tumor-microenvironment-on-a-chip: the construction and application","volume":"22","author":"Xu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.intimp.2026.116797_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1712796","article-title":"My cells, my model: immune-competent autologous organ-on-chip systems as a new paradigm in precision medicine","volume":"16","author":"Bisconti","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116797_bb0720","doi-asserted-by":"crossref","DOI":"10.1007\/7651_2025_676","article-title":"High-throughput drug testing and synergy evaluation in patient-derived tumor organoids: a practical guide","author":"Yilmaz","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.intimp.2026.116797_bb0725","first-page":"525","article-title":"AI-enabled organoids: construction, analysis, and application","volume":"31","author":"Bai","year":"2024","journal-title":"Bioact. Mater."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0730","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","article-title":"Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells","volume":"31","author":"Maulana","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0735","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41587-022-01397-w","article-title":"Uncovering the mode of action of engineered T cells in patient cancer organoids","volume":"41","author":"Dekkers","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116797_bb0740","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/0008-5472.CAN-24-1875","article-title":"Adenosine uptake through the nucleoside transporter ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis","volume":"85","author":"Allard","year":"2025","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116797_bb0745","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming Cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0750","article-title":"Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy","volume":"5","author":"Mpekris","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.intimp.2026.116797_bb0755","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116797_bb0760","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41540-024-00450-5","article-title":"Immune digital twins for complex human pathologies: applications, limitations, and challenges","volume":"10","author":"Niarakis","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"issue":"11","key":"10.1016\/j.intimp.2026.116797_bb0765","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jcyt.2025.07.002","article-title":"Cytokine release syndrome risk model with T-cell engaging therapies","volume":"27","author":"Lafeuille","year":"2025","journal-title":"Cytotherapy"},{"issue":"14","key":"10.1016\/j.intimp.2026.116797_bb0770","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.intimp.2026.116797_bb0775","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/cts.13501","article-title":"Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a phase I study of bispecific antibody, mosunetuzumab","volume":"16","author":"Susilo","year":"2023","journal-title":"NHL, Clin Transl Sci"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:01:18Z","timestamp":1789243278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":155,"alternative-id":["S1567576926006430"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116797","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering spatial-temporal mechanisms of PD-1 blockade resistance via biologically informed machine learning","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116797"}}